Written by Seyd Hamid Mousavi, Masumeh Eftekhari Shirkuhi
Introduction: Inflammatory bowel disease is a chronic and degenerative disease of the digestive tract. In order to reduce the long-term complications of IBD, the goal of treatment in these patients is mucosal repair. Recently, it has been shown that level of fecal Calprotectin is a marker that shows mucosal repair in IBD patients. Therefore, the aim of this study was to determine the relationship between fecal calprotectin level with endoscopic imaging and mucosal repair in patients with IBD in Bandar Abbas during the years 2017 to 2018.
Method: This is a descriptive-analytic study done in Bandar Abbas during 2017-2018 on IBD patients. Fecal calprotectin, colonoscopy, CDEIS, and UCEIS were used to evaluate the severity of the disease in all patients. All patients were evaluated for recurrence, symptoms and severity of the disease, as well as colonoscopic findings. Calprotectin was measured in follow up and its association with the symptoms of the disease was evaluated.
Results: In this study, 373 patients were studied. Of the subjects, 74 patients (19.8%) were in the group of patients with Crohn's disease and 299 (80.2%) were in the group of patients with ulcerative colitis. Based on the findings of this study, higher concentrations of UCEIS were associated with higher levels of calprotectin in patients with ulcerative colitis (r = 0.517; p <0.001). Also in Crohn's patients, higher levels of CDEIS were associated with higher levels of calprotectin (r = 0.473; p <0.001).
Discussion: Levels of fecal calprotectin are associated with endoscopic activity in inflammatory bowel disease. This suggests that this test can be used to predict the disease's active status.
Keywords: Fecal calprotectin, endoscopic remission, mucosal repair, inflammatory bowel disease